Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
Authors:
- 8 September 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 75, 128977
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cureWorld Journal of Gastroenterology, 2021
- New Approaches to the Treatment of Chronic Hepatitis BJournal of Clinical Medicine, 2020
- Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of ActionJournal of Medicinal Chemistry, 2018
- Perspectives and limitations for nucleo(t)side analogs in future HBV therapiesCurrent Opinion in Virology, 2018
- An Overview of Hepatitis B Virus Surface Antigen Secretion InhibitorsFrontiers in Microbiology, 2018
- Hepatitis B cure: From discovery to regulatory approvalJournal of Hepatology, 2017
- Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus InfectionJournal of Medicinal Chemistry, 2017
- Novel targets for hepatitis B virus therapyLiver International, 2017
- Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis BCold Spring Harbor Perspectives in Medicine, 2015
- HBV and the immune responseLiver International, 2014